SecBot SecBot
PRESS-RELEASE ·Filed Mar 3, 2026

ABEO

Abeona Therapeutics Inc.
NEUTRAL
Impact 3/10
Horizondays Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Traders should prepare for the earnings call on March 17 for potential updates on ZEVASKYN commercial performance, manufacturing capacity, and financial runway. Absence of data suggests this release is logistical, not substantive.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$4.94
T+0 close · Mar 3, 2026 · via day close
Latest settled
+15.18%
T+60 · $5.69
Vs SPY
+4.87%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 3 $4.94entry
  2. T+1 · 9mo ago +0.61%α −0.15% · $4.97
  3. T+5 · 8mo ago +4.05%α +4.53% · $5.14
  4. T+20 · 8mo ago −9.31%α −4.91% · $4.48
  5. T+60 · 6mo ago +15.18%α +4.87% · $5.69
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Abeona Therapeutics announced it will discuss its fourth quarter and full year 2025 financial results on March 17, 2026, but did not release any actual financial data in this press release. The company highlighted its commercial-stage status with ZEVASKYN® and upcoming participation in the Leerink Global Healthcare Conference.

Key Facts

  • Abeona Therapeutics will host an earnings call on March 17, 2026, to discuss Q4 and full year 2025 financial results.
  • No financial results were disclosed in this press release.
  • The company is commercializing ZEVASKYN®, an autologous cell-based gene therapy for RDEB.
  • Management will participate in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026.
  • Forward-looking statements emphasize risks related to commercialization, manufacturing, regulatory approvals, and patient enrollment.

Financial Impact

No financial data released, impact cannot be quantified at this time

Risk Factors

  • Risk that ZEVASKYN fails to gain market traction or that manufacturing cannot scale to meet demand.
  • Regulatory risk related to FDA inspections of the cGMP manufacturing facility.
  • Clinical trial enrollment challenges could delay development programs.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3248223

Track record

29 reports on ABEO

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +15.24% at T+20 after the Sep 29, 2026 report. 4 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
  2. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $2.30 Now $2.60 +13.04% settles Nov 17
  3. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $2.29 to $2.42 Now $2.60 +13.54% ▲ +5.68% +6.04% vs SPY
  4. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
  5. Nov 9, 20267d ago 8-K Bearish 6/10 Entry $2.54 to $2.46 Now $2.60 −2.36% ▲ +3.35% +2.98% vs SPY
  6. Nov 9, 20267d ago Press Release Mixed 6/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
  7. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $4.17 to $2.54 Now $2.60 −37.65% ▼ −39.09% −41.46% vs SPY
  8. Oct 23, 202624d ago SC 13D Bullish 6/10 Entry $4.40 to $4.31 Now $2.60 −40.91% ▼ −2.05% −2.76% vs SPY
  9. Sep 29, 20266w ago Insider Cluster Bearish 4/10 Entry $5.25 to $5.01 Now $2.60 +50.48% ▲ +4.57% +4.75% vs SPY
  10. Sep 18, 20268w ago Press Release Bullish 6/10 Entry $5.57 to $5.67 Now $2.60 −53.32% ▲ +1.80% +0.24% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens Wed (10h 30m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 3, 2026